Clinical Laserthermia Systems AB (https://clinicallaser.se/en/svenska-terapi/svenska-principer/) (publ) (CLS) is preparing to enter into an agreement under which the company’s technology and products will be used in a clinical trial, carried out by the American biotech company Immunophotonics Inc. The purpose of the trial is to evaluate the efficacy of a new IP-001-drug from Immunophotonics, developed to create, or enhance, an immune response in connection with ablation treatment. The trial, planned to be carried out at a number of hospitals in Switzerland, will be financed by

Source: CLS’ products and method are planned to be used in a clinical trial, carried out by Immunophotonics, regarding evaluation of new drug